ScholarIQanswers from OpenAlex
Osaka Red Cross Hospital
InstitutionResearch output, impact & collaborations
Osaka Red Cross Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Osaka Red Cross Hospital?
ScholarIQrecord summary
Osaka Red Cross Hospital is a research organisation in Osaka, JP. OpenAlex records 2,714 works and 102,968 citations for it. 588 researchers list it as their most recent affiliation.
How many works does Osaka Red Cross Hospital have?
ScholarIQindexed works
Osaka Red Cross Hospital has 2,714 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Osaka Red Cross Hospital have?
ScholarIQcitation count
Osaka Red Cross Hospital has 102,968 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Osaka Red Cross Hospital?
ScholarIQresearcher count
Osaka Red Cross Hospital has 588 researchers in the ScholarIQ index.
What is the average h-index at Osaka Red Cross Hospital?
ScholarIQavg h-index
Osaka Red Cross Hospital has an average h-index of 103 in OpenAlex.
What is the ROR of Osaka Red Cross Hospital?
ScholarIQror
The ROR for Osaka Red Cross Hospital is on the source record.
What is the OpenAlex record for Osaka Red Cross Hospital?
ScholarIQopenalex
The OpenAlex for Osaka Red Cross Hospital is on the source record.
Who are the most-cited researchers behind Osaka Red Cross Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Osaka Red Cross Hospital?
ScholarIQmost cited works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, Jose M. Pacheco, M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Jänne
How much of the research on Osaka Red Cross Hospital is open access?
ScholarIQopen access share
25%OPEN ACCESS